Keros Therapeutics, Inc.
KROS
$9.93
-$0.14-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.05% | -222.27% | 76.28% | -120.68% | 422.54% |
| Total Depreciation and Amortization | 0.75% | 1.27% | 6.76% | 7.56% | 3.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.79% | 72.54% | -49.63% | -3.43% | -3.33% |
| Change in Net Operating Assets | 206.43% | -319.52% | 165.78% | -387.47% | 129.04% |
| Cash from Operations | 87.07% | -940.01% | 110.97% | -118.38% | 450.31% |
| Capital Expenditure | 45.52% | -1.52% | 81.67% | -27.43% | -95.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 45.52% | -1.52% | 81.67% | -27.43% | -95.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.49% | -9.29% | 723.53% | 325.00% | -99.99% |
| Repurchase of Common Stock | 99.39% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 99.39% | -270,550.71% | 723.53% | 325.00% | -99.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.54% | -12,567.21% | 110.74% | -118.88% | 449.15% |